Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05262361 · ClinicalTrials.gov registry record · NA
Persistent Post-Concussion Symptoms With Convergence Insufficiency
A NA study, sponsored by New Jersey Institute of Technology.
- Completed
- Registry status
- NA
- Development phase
- 112
- Enrollment target
NCT05262361 is a NA study that has completed, run by New Jersey Institute of Technology. The registered enrollment target is 112 participants.
The verdict
NCT05262361, a NA study, has completed, sponsored by New Jersey Institute of Technology.
- COMPLETED
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
Study Summary
Our successful R01 discovered 1) the neural mechanistic difference between typically occurring convergence insufficiency (TYP-CI) and binocularly normal controls and 2) the underlying mechanism of office-based vergence and accommodative therapy (OBVAT) that is effective in remediating symptoms. Adolescent and young adult concussion is considered a substantial health problem in the United States where our team has shown that about half of patients with persistent post-concussion symptoms have convergence insufficiency (PPCS-CI), causing significant negative impact associated with reading or digital screen-related activities, and is believed to be one factor causing delayed recovery impacting return to school, sports, or work. The results of this randomized clinical trial will impact the lives of adolescents and young adults with PPCS-CI to guide professionals on how to manage and treat those with PPCS-CI by 1) comparing the differences between PPCS-CI and TYP-CI, 2) discovering the neural mechanism of OBVAT for PPCS-CI compared to standard-community concussion care, and 3) determining the effectiveness of 12 one-hour sessions compared to 16 one-hour sessions of OBVAT.
Interventions
- BEHAVIORAL Office-based Vergence and Accommodative Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2026-01-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05262361
The ClinicalTrials.gov registry entry for NCT05262361 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Jersey Institute of Technology, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Office-based Vergence and Accommodative Therapy is the first listed.
NCT05262361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05262361 about?
NCT05262361 is a clinical study titled "Persistent Post-Concussion Symptoms With Convergence Insufficiency". Our successful R01 discovered 1) the neural mechanistic difference between typically occurring convergence insufficiency (TYP-CI) and binocularly normal controls and 2) the underlying mechanism of office-based vergence and accommodative therapy (OBVAT) that is effective in remediating symptoms. Adol...
What is the current status of trial NCT05262361?
This trial is currently completed. It is a NA study. The enrollment target is 112 participants. The study started on 2021-09-01. Estimated completion is 2026-01-19.
What interventions are being tested in trial NCT05262361?
The interventions under investigation include: Office-based Vergence and Accommodative Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT05262361?
This trial is sponsored by New Jersey Institute of Technology, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.